Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clopidogrel
Drug ID BADD_D00504
Description Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Indications and Usage Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
Marketing Status approved
ATC Code B01AC04
DrugBank ID DB00758
KEGG ID D07729; D10823; D10824
MeSH ID D000077144
PubChem ID 60606
TTD Drug ID D0N0TZ
NDC Product Code 42543-714; 50090-4918; 52605-083; 16729-218; 0024-1171; 68788-8190; 72578-012; 65977-0037; 52605-082; 63187-362; 63629-4728; 70518-0400; 33342-060; 42543-713; 65162-414; 0093-7314; 16729-219; 61919-007; 67296-1840; 50090-2598; 50090-5781; 0024-1332; 61919-737; 70771-1062; 16714-052; 68071-2813; 68071-4138; 71335-0581
UNII A74586SNO7
Synonyms Clopidogrel | SC 25989C | SC 25990C | SR 25989 | Clopidogrel-Mepha | Clopidogrel Mepha | Clopidogrel Sandoz | Iscover | Clopidogrel Napadisilate | Clopidogrel Hydrochloride | PCR 4099 | PCR-4099 | Clopidogrel Besylate | Clopidogrel Besilate | Clopidogrel, (+)(S)-isomer | Plavix | Clopidogrel Bisulfate
Chemical Information
Molecular Formula C16H16ClNO2S
CAS Registry Number 113665-84-2
SMILES COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemodynamic instability24.03.02.0060.000235%Not Available
Eye pruritus06.04.05.006--Not Available
Lymphatic disorder01.09.01.003--Not Available
Diastolic dysfunction02.04.02.0220.000032%Not Available
Large intestinal haemorrhage24.07.02.026; 07.12.03.0030.000064%
Eosinophilic pneumonia acute22.01.01.008; 01.02.04.0040.000032%Not Available
Epigastric discomfort07.01.02.0040.000053%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Organ failure08.01.03.0410.000021%Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000064%Not Available
Acquired haemophilia01.01.01.0020.000160%Not Available
Cerebral haematoma24.07.04.006; 17.08.01.0140.000342%Not Available
Vanishing bile duct syndrome09.02.03.0030.000075%Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Haemorrhoidal haemorrhage07.15.03.002; 24.10.02.0010.000053%
Haemorrhagic transformation stroke17.08.01.036; 24.07.04.0180.000086%Not Available
Haemorrhage24.07.01.0020.001829%Not Available
Haemorrhage urinary tract24.07.01.007; 20.02.03.0050.000043%Not Available
Pulmonary mass22.02.07.0040.000101%Not Available
Intra-abdominal haematoma24.07.02.034; 07.12.02.0050.000075%Not Available
Gaze palsy17.02.05.044; 06.05.02.0140.000021%Not Available
Gastrointestinal ulcer haemorrhage24.07.02.023; 07.04.04.006--Not Available
Colitis microscopic07.08.01.0110.000032%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000064%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000278%Not Available
Metabolic disorder14.11.01.0010.000047%Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.000053%Not Available
Pulseless electrical activity02.03.04.0200.000021%Not Available
Retroperitoneal haematoma24.07.01.060; 07.07.02.0050.000385%Not Available
Nuchal rigidity17.05.02.006; 15.05.04.0050.000053%Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene